Gail Boxer Marcus Sells 11,000 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) Director Gail Boxer Marcus sold 11,000 shares of Natera stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $217.21, for a total value of $2,389,310.00. Following the transaction, the director owned 6,183 shares of the company’s stock, valued at $1,343,009.43. The trade was a 64.02% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Natera Stock Performance

NASDAQ NTRA opened at $216.50 on Thursday. The stock has a 50-day simple moving average of $205.93 and a two-hundred day simple moving average of $216.10. The firm has a market capitalization of $31.00 billion, a P/E ratio of -132.82 and a beta of 1.56. Natera, Inc. has a fifty-two week low of $131.81 and a fifty-two week high of $256.36.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Robinhood Asset Management LLC acquired a new position in shares of Natera during the 4th quarter worth approximately $12,981,000. JPMorgan Chase & Co. boosted its holdings in shares of Natera by 9.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 11,628,914 shares of the medical research company’s stock worth $1,871,914,000 after purchasing an additional 1,003,129 shares during the last quarter. Krilogy Financial LLC acquired a new position in Natera in the third quarter valued at approximately $1,323,000. Zweig DiMenna Associates LLC lifted its holdings in Natera by 6.8% in the third quarter. Zweig DiMenna Associates LLC now owns 132,500 shares of the medical research company’s stock valued at $21,329,000 after acquiring an additional 8,400 shares during the last quarter. Finally, Systrade AG acquired a new position in Natera in the fourth quarter valued at approximately $11,454,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on NTRA. Weiss Ratings restated a “sell (d-)” rating on shares of Natera in a research note on Tuesday, April 21st. William Blair began coverage on Natera in a research note on Tuesday, April 14th. They issued an “outperform” rating for the company. Evercore restated an “outperform” rating and issued a $270.00 price target on shares of Natera in a research note on Friday, May 8th. Wolfe Research started coverage on Natera in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $260.00 price objective for the company. Finally, Morgan Stanley cut their price objective on Natera from $265.00 to $250.00 and set an “overweight” rating for the company in a research note on Tuesday, March 3rd. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $256.12.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.